Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.32 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28302773 | 0.82 | LOXL2 (0.50) | LOXL2CYP2A6 | |
| SCHEMBL16958767 | 0.82 | GRM5 (0.33) | LOXL2CYP2A6 | |
| SCHEMBL28049287 | 0.82 | GRM5 (0.31) | LOXL2CYP2A6 | |
| SCHEMBL6958311 | 0.82 | KDM4E (0.34) | LOXL2CYP2A6 | |
| SCHEMBL458972 | 0.82 | CYP2A6 (0.50) | LOXL2CYP2A6GLA | |
| SCHEMBL6965146 | 0.82 | CYP2A6 (0.31) | LOXL2CYP2A6 | |
| SCHEMBL27491 | 0.79 | TSHR (0.38) | LOXL2CYP2A6 | |
| SCHEMBL16959461 | 0.79 | MEN1 (0.38) | LOXL2CYP2A6HRH3GLA | |
| SCHEMBL6958848 | 0.79 | CYP2A6 (0.33) | LOXL2CYP2A6GLA | |
| SCHEMBL9644543 | 0.77 | GLA (0.36) | LOXL2CYP2A6GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144872-A1 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation | BIOLIPOX AB | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144872-A1 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | LOXL2 22/4885CYP2A6 362/4885SAE1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.